北京科兴与GSK中国签署独家销售服务协议

    北京科兴8月1日宣布与葛兰素史克（中国）投资有限公司（简称GSK中国）签署独家销售服务协议，双方将在中国大陆地区联合销售北京科兴研发生产的季节性流感疫苗安尔来福。GSK中国将负责销售安尔来福的成人剂型，而北京科兴则利用已经建立的销售网络继续销售安尔来福的儿童剂型。
    由北京科兴自主研发和生产的流感裂解疫苗安尔来福于2005年获得新药证书，2006年秋季正式上市。该疫苗经临床试验证明其安全性和免疫效果均不低于进口同类产品。
    北京科兴总经理尹卫东先生认为：“这次与GSK中国合作，将统和两家公司市场销售团队的力量，实现强强联合，为安尔来福的销售创造出协同效应。与GSK在商业上的合作，标志着北京科兴在与全球知名的生物制药企业的合作上迈出了重要的一步。”
    GSK中国大中华区总裁黄秀美女士说：“保护中国民众免于流感的危害对于我们这个行业和卫生部门来说是一个重大的挑战。这项合作协议表明了GSK愿意与本地的合作伙伴共同承担这个挑战。北京科兴是中国最活跃的流感疫苗生产企业之一。我们期待着GSK与北京科兴的进一步合作。GSK将继续为中国人民的健康和长寿而努力。”

附：英文全文

Sinovac Enters Exclusive Promotion Service Agreement with GlaxoSmithKline (China) Investment Co., Ltd.
Wednesday August 1, 8:00 am ET
BEIJING, Aug. 1 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of biopharmaceutical products in China, today announced it has entered into an Exclusive Promotion Service Agreement with GlaxoSmithKline (China) Investment Co., Ltd. (or "GSK China"). GSK China and Sinovac will market and promote Anflu®, a seasonal influenza vaccine developed and manufactured by Sinovac.
 
GSK China's sales team will focus on the distribution of the adult dosage formulation and Sinovac will sell the pediatric dosage formulation, utilizing its established sales force that has a track record of targeting the pediatric market.
 
Mr. Weidong Yin, President and CEO of Sinovac, commented, "This collaboration with GSK China will leverage the strengths of the two companies' sales and marketing teams, creating synergy for the distribution of Anflu®. Seizing this partnering opportunity with a well-known, global pharmaceutical company represents a significant step for Sinovac. We will continue to execute this strategy in order to increase shareholder value."
 
Amy Huang, Area Director for GSK China/HK, added, "To protect people from flu in China -- seasonal or pandemic -- is an important challenge for our industry and the health authorities. This agreement reflects GSK's willingness to work with local partners to take on this challenge. Sinovac is one of the most active Chinese vaccine manufacturers, in both seasonal and pandemic flu franchises, and we anticipate a lot of synergy between GSK and Sinovac. GSK remains committed to do more for the Chinese people, and help the people of China feel better and live longer."
 
About Influenza
Influenza, commonly known as the flu, is an acute respiratory infection that is very contagious. In a typical flu season, between 5 to 10% of the world's population (300 to 600 million people) is infected. Influenza epidemics typically occur during the winter months and are responsible for as many as 200,000 hospitalizations and 36,000 deaths a year in the United States alone. Influenza viruses may also cause a "pandemic", during which rates of illness and death from influenza-related complications can increase dramatically worldwide. Since the influenza virus tends to mutate constantly, it is very difficult to treat. There is no effective cure. Therefore, vaccination is the only effective defense against outbreaks of influenza.